at Zacks.com (Oct 30, 2014)
Synergy Pharmaceuticals (SGYP +5.3%) moves up after saying its commenced Phase IIb clinical trials of plecanatide, a treatment for patients with constipation-predominant irritable bowel syndrome. The trial is being conducted at 70 sites in the U.S. and includes 350 patients. Parexel International (PRXL -2%) is the contract research organization for the trial.
From other sites
at MarketWatch.com (Jan 2, 2013)
at Fox Business (Aug 30, 2012)
at MarketWatch.com (May 4, 2012)